GlassScriptPhysician profile
Stephen L Blum
NPI 1659389724
$2,383.48
in general payments reported to CMS, 2019-2025
26 companies · $317 in 2025
The $317 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $146 · 2020: $284 · 2021: $346 · 2022: $389 · 2023: $424 · 2024: $477 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,154 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,153.50 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $485.49 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $238.70 | 2020-2024 | |
| Janssen Biotech, INC. | $226.76 | 2024-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $190.43 | 2021-2025 | |
| Amgen INC. | $184.98 | 2020-2021 | |
| Sun Pharmaceutical Industries INC. | $157.78 | 2021-2025 | |
| Ucb, INC. | $155.15 | 2022-2025 | Bimzelx, Cimzia |
| Incyte Corporation | $105.01 | 2022-2024 | Opzelura |
| Leo Pharma INC. | $80.54 | 2023-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $76.64 | 2019-2025 | Ebglyss, Taltz |
| E.R. Squibb & Sons, L.L.C. | $59.79 | 2023-2024 | Sotyktu |
| Pfizer INC. | $48.32 | 2019-2024 | |
| Vyne Pharmaceuticals INC. | $47.72 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $47.60 | 2021-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $45.26 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $40.84 | 2021-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Journey Medical Corporation | $38.52 | 2021-2023 | |
| Medimetriks Pharmaceuticals, INC. | $33.54 | 2023-2025 | Neo-Synalar, Clindacin Etz |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.16 | 2022 | |
| Genzyme Corporation | $18.65 | 2022 | |
| Genentech USA, INC. | $18.24 | 2024 | Xolair |
| Dermavant Sciences, INC. | $14.58 | 2023 | Vtama |
| Almirall LLC | $13.88 | 2019 | |
| Celgene Corporation | $12.29 | 2019 | |
| Organon LLC | $11.63 | 2025 | Vtama |
| Merck Sharp & Dohme LLC | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Blum listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.